Not a bad quarterly.
Income higher and cost lower compared to last quarter. Product enhancements of $510k put the quarter into a negative cash flow, otherwise it was positive.
Some of the contract won over the last year will have a full year of ongoing payments so we should see this part continue to grow.
Over the full year they remain under the $20m threshold which means they are still eligible for the R&D refund.
While the topline revenue hasn't grown, the bottom has improved as costs and pass through revenue has reduced as the new product is cheaper to run.
They also seem to think that they are starting to get some traction in the Aged Care market which will be sticky revenue.
Not a bad quarterly. Income higher and cost lower compared to...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SW1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.810M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3272 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 563660 | 2 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| SW1 (ASX) Chart |
Day chart unavailable